PHASEBIO PHARMA Accounts Payable

Accounts Payable of PHAS for past 10 years: annual, quarterly and twelve month trailing (TTM) including Accounts Payable growth rates and interactive chart. Accounts payable (AP) represents a company's obligation to pay off a short-term debt to its creditors or suppliers. Accounts payable are amounts due to vendors or suppliers for goods or services received that have not yet been paid for. The sum of all outstanding amounts owed to vendors is shown as the accounts payable balance on the company's balance sheet. The increase or decrease in total AP from the prior period appears on the cash flow statement.


Highlights and Quick Summary

  • Accounts Payable for the quarter ending June 29, 2021 was $2.96 Million (a -49.85% decrease compared to previous quarter)
  • Year-over-year quarterly Accounts Payable increased by 39.27%
  • Annual Accounts Payable for 2020 was $3.67 Million (a 25.78% increase from previous year)
  • Annual Accounts Payable for 2019 was $2.92 Million (a 61.74% increase from previous year)
  • Annual Accounts Payable for 2018 was $1.81 Million (a 320.0% increase from previous year)
Visit stockrow.com/PHAS for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Accounts Payable of PHASEBIO PHARMA

Most recent Accounts Payableof PHAS including historical data for past 10 years.

Interactive Chart of Accounts Payable of PHASEBIO PHARMA

PHASEBIO PHARMA Accounts Payable for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 $2.96 $5.9
2020 $3.67 $2.12 $6.97 $1.92 $3.67
2019 $2.92 $1.66 $3.05 $2.06 $2.92
2018 $1.81 $1.58 $1.81
2017 $0.43
2016 $0.43

Business Profile of PHASEBIO PHARMA

Sector: Healthcare
Industry: Biotechnology
PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiopulmonary diseases. Its lead product candidate is bentracimab (PB2452), a reversal agent for the antiplatelet drug ticagrelor that is in Phase III clinical trial for patients with uncontrolled major or life-threatening bleeding events or in patients requiring urgent or emergency surgery. The company is also developing PB1046, a vasoactive intestinal peptide analogue that is in Phase IIb clinical trial for the treatment of pulmonary arterial hypertension; and PB6440 for the treatment of resistant hypertension. The company has a co-development agreement with SFJ Pharmaceuticals X, Ltd. to develop PB2452, a reversal agent for the antiplatelet drug ticagrelor. PhaseBio Pharmaceuticals, Inc. was incorporated in 2002 and is based in Malvern, Pennsylvania.